Atrial Fibrillation Device Market
Atrial Fibrillation Device Market Analysis by Electrophysiology Diagnostics and Therapeutics Done at Hospitals, Ambulatory Surgical Centers, and Cardiac Catheterization Labs from 2024 to 2034
Analysis of Atrial Fibrillation Device Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Atrial Fibrillation Device Market Outlook (2024 to 2034)
The global atrial fibrillation device market size is pegged at a valuation of US$ 6.52 billion in 2024 and is forecasted to jump to US$ 24.76 billion by the end of 2034. Worldwide sales of atrial fibrillation devices are projected to rise at an astronomical 14.3% CAGR from 2024 to 2034.
Atrial fibrillation is a condition where the heart rhythm is very fast or irregular. This is also known as cardiac arrhythmia and can lead to the formation of blood clots in the heart raising the risk of heart failure, stroke, or other cardiac complications.
Increasing prevalence of cardiac disorders, growing adoption of unhealthy lifestyles, rising levels of stress among people resulting in hypertension issues, expanding senescent population, and advancements in atrial fibrillation treatment technologies are key prospects that could boost atrial fibrillation device market growth over the coming years.
Growing popularity of minimally invasive surgeries is projected to uplift the demand for catheter-based ablation and maze surgical ablation among people suffering from atrial fibrillation. Rising awareness regarding the symptoms and diagnosis of cardiac arrhythmia is also estimated to drive the sales of atrial fibrillation devices over the decade.
Rising investments in healthcare infrastructure development and atrial fibrillation research are also slated to create new opportunities for atrial fibrillation device distributors going forward. Regulatory bodies around the world are continually approving innovative atrial fibrillation treatment equipment thereby boosting market development as well.
- In August 2023, Biosense Webster Inc., a renowned name in the arrhythmia care space, announced that it had received approval for several atrial fibrillation products to be used in a workflow without fluoroscopy. This is the first-of-its-kind approval from the United States Food & Drug Administration (FDA) for atrial fibrillation ablation.
On the contrary, high costs associated with atrial fibrillation procedures and the dearth of skilled medical professionals are forecasted to substantially impede atrial fibrillation device sales through 2034. Atrial fibrillation device manufacturers should focus on making their products more cost-effective and simple to get over the aforementioned restraints and attain the full growth scope of the market.
| Report Attributes | Details |
|---|---|
| Atrial Fibrillation Device Market Size (2024E) | US$ 6.52 Billion |
| Projected Market Value (2034F) | US$ 24.76 Billion |
| Global Market Growth Rate (2024 to 2034) | 14.3% CAGR |
| East Asia Market Value (2024E) | US$ 2.75 Billion |
| North America Market Share (2034F) | 37.9% |
| Cryotherapy Atrial Fibrillation Device Segment Growth (2024 to 2034) | 15.2% CAGR |
| Key Companies Profiled |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Which Start-ups are Transforming the Atrial Fibrillation Business Space?
“AtriAN Medical, Ablacon, Rhythm AI, and Cortify Key Innovators in the Market”
Product innovation is projected to be of the essence for any new atrial fibrillation device manufacturer looking to make a mark in this marketplace. Technologies such as artificial intelligence and machine learning are projected to be crucial to the development of advanced atrial fibrillation systems of tomorrow. Pulsed field ablation therapy is projected to gain massive popularity in the atrial fibrillation treatment landscape over the next ten years and beyond.
- AtriAN Medical, a new medical device company based in Ireland, is focusing on providing medical devices that target the origin of atrial fibrillation. The company provides a unique non-thermal ablation solution that utilizes micro pulsed electric fields (mPEF) to ablate cells and leave other myocardial tissues unaffected.
- Rhythm AI, an innovative British start-up is deploying proprietary AI algorithms to identify target regions in the heart for different cardiac procedures. The company offers an AI-based solution called STAR Mapping for catheter ablation of atrial fibrillation.
- Cortify Care, a new company focused on solving cardiac arrhythmias, provides a novel non-invasive medical device platform to precisely map arrhythmia. The platform is called Acorys and consists of a biopotential amplifier, ECG electrodes, and an image processing solution.
Aspiring atrial fibrillation device providers will also need huge capital to fund their business expansion and product development efforts, which is why financing rounds are projected to emerge as one of the most popular atrial fibrillation device market trends in the future.
- In April 2019, Ablacon Inc., a new company based in the United States and founded in 2015, announced that it had raised US$ 21.5 million in a Series A funding round. The capital raise was led by Ajax Health and the company intended to use this funding to further develop its advancement mapping system for treatment guidance in atrial fibrillation cases.
Fact.MR, a market research and competitive intelligence provider, in this latest atrial fibrillation device market study report, gives a detailed regional analysis of the industry with factors such as local supply, pricing trends, product standards, safety regulations, and new developments, affecting market growth.
Country-wise Insights
China, India, the United States, Sweden, Japan, and Austria are some of the most prominent countries where demand for atrial fibrillation devices is projected to soar high by the end of the study period owing to the rising number of cardiac disorders.
Why Should Atrial Fibrillation Device Manufacturers Target China?
“Rapidly Surging Incidence of Diabetes Creating Business Growth Potential”
| Attribute | China |
|---|---|
| Market Value (2024E) | US$ 378 Million |
| Growth Rate (2024 to 2034) | 15.9% CAGR |
| Projected Value (2034F) | US$ 1.64 Billion |
People affected by diabetes are prone to many health complications and disorders such as hypertension, atrial fibrillation, foot damage, etc. The prevalence of diabetes in China has been increasing rapidly in the past four decades and this trend is projected to further bolster demand for atrial fibrillation equipment over the coming years.
- As per an article published by WebMD, people suffering from type 1 and type 2 diabetes are at a greater risk of developing atrial fibrillation while people with type 2 diabetes are 40% more likely to develop this health complication.
Increasing focus on healthcare infrastructure development, growing medical tourism, and rising availability of novel atrial fibrillation ablation solutions are other factors that could contribute to the growing atrial fibrillation device market size in China in the future.
What Makes the United States a Key Market for Atrial Fibrillation Devices?
“Increasing Availability of Novel Atrial Fibrillation Systems”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 2.55 Billion |
| Growth Rate (2024 to 2034) | 12.2% CAGR |
| Projected Value (2034F) | US$ 8.11 Billion |
Surging use of advanced healthcare technologies and high investments in R&D of novel atrial fibrillation treatment devices are projected to make the United States a highly opportune space for atrial fibrillation device suppliers. Growing number of regulatory approvals for new medical devices and frequent launches of innovative atrial fibrillation equipment are estimated to boost atrial fibrillation device market growth in the country going forward.
- In July 2023, Biosense Webster, a leading name in the treatment and diagnosis of heart rhythm disorders, announced the launch of a new catheter to map complex cardiac arrhythmias in the United States. Optrell Mapping Catheter with TrueRef Technology was cleared by the United States FDA back in 2022.
- In May 2023, Bayer, a global leader in the healthcare business, announced that it had received a fast track clearance for its asundexian Atrial fibrillation program from the United States FDA. The drug is probably projected to be used in the treatment of atrial fibrillation stroke and systemic embolism as well.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Category-wise Insights
Atrial fibrillation device manufacturers are focusing on incorporating advanced technologies in their products and maximizing their sales revenue from hospitals around the world.
Where are Most Atrial Fibrillation Devices Used?
“Hospitals to Spearhead Global Sales of Atrial Fibrillation Devices”
| Attribute | Hospitals |
|---|---|
| Segment Value (2024E) | US$ 5.35 Billion |
| Growth Rate (2024 to 2034) | 14.2% CAGR |
| Projected Value (2034F) | US$ 20.15 Billion |
Hospitals provide excellent pre and post-procedure care for all patients and this is why most patients prefer to get their atrial fibrillation treatments done in this setting. Rising number of atrial fibrillation procedures being performed in hospitals is projected to uplift atrial fibrillation device sales in this segment over the coming years.
Competitive Landscape
Top atrial fibrillation device companies are focusing on taking innovative approaches to the treatment of atrial fibrillation and launching new products to boost their revenue generation.
- In August 2023, GE Healthcare, a global leader in medical technology, announced the launch of its new digital tool to support people undergoing atrial fibrillation treatment. CardioVisio allows clinicians to visualize data related to disease progression to improve patient outcomes and overall clinical decisions.
Atrial fibrillation device producers are also engaging in capital raise activities to finance their R&D divisions and improve their business potential to gain a competitive edge over other market players.
- In September 2023, Field Medical, a new company based in California, United States, announced that it had raised US$ 14 million in a seed round. The company is working on developing next-generation pulsed field ablation therapy and intends to use the raised capital to advance its business efforts and launch in-human clinical trials for the same in 2024.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Key Segments of Atrial Fibrillation Device Market Research
-
By Product Type :
- Electrophysiology Diagnostics
- Conventional
- Steerable
- Fixed
- Advanced EP Mapping Catheters
- Coronary Sinus Catheters
- Intracardiac Catheters
- Conventional
- Therapeutics
- EP Ablation Catheters
- RF Ablation Catheters
- Conventional RF Catheter Ablation
- Irrigated RF Catheter Ablation
- Cryoablation
- Single Electrode Cryoablation Catheters
- Multi-electrode Cryoablation Catheters
- Epicardial Catheters Ablation
- RF Ablation Catheters
- Maze Surgery
- RF Ablation Clamps
- Cryprobes
- LAA Management Devices
- EP Ablation Catheters
- Electrophysiology Diagnostics
-
By Technology :
- Radiofrequency
- Cryotherapy
- Ultrasound
- Others
-
By End User :
- Hospitals
- Ambulatory Surgical Centers
- Cardiac Catheterization Labs
-
By Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia & Oceania
- Middle East & Africa
- FAQs -
How big is the atrial fibrillation device market in 2024?
The global atrial fibrillation device market is estimated to be valued at US$ 6.52 billion in 2024.
What is the projected market valuation for 2034?
Sales of atrial fibrillation devices are forecasted to reach US$ 24.76 billion by 2034-end.
How fast will sales of atrial fibrillation devices rise in the future?
Atrial fibrillation device demand is set to increase at a phenomenal 14.3% CAGR from 2024 to 2034.
Where is the demand for atrial fibrillation devices high?
North America is projected to account for 44% of global atrial fibrillation device sales in 2024.
At what pace will atrial fibrillation device sales increase in South Korea?
Sales of atrial fibrillation devices in South Korea are forecasted to rise at 18.8% CAGR over the next ten years.
Who are the top atrial fibrillation device distributors?
Japan Lifeline Co., Biomerics, Abbott Laboratories, ArtiCure Inc., Biotronik Inc., and Boston Scientific Corporation are leading manufacturers of atrial fibrillation devices.
Atrial Fibrillation Device Market